Please login to the form below

Not currently logged in


This page shows the latest Luxturna news and features for those working in and with pharma, biotech and healthcare.

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

Two cell therapies, Novartis’Kymriah and Gilead’s Yescarta, are approved in the US, as is Spark’s gene therapy Luxturna, while GSK’s Strimvelis is approved only in Europe.

Latest news

More from news
Approximately 5 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    For example, the ophthalmic drug Luxturna, approved last year, costs $850, 000 per dose. ... For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Transforming healthcare through effective collaboration. Making work to feel proud of.

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....